Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
Public ClinicalTrials.gov record NCT04338022. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Study identification
- NCT ID
- NCT04338022
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Enrollment
- 1,124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 11, 2020
- Primary completion
- Oct 1, 2023
- Completion
- Mar 7, 2024
- Last update posted
- Jun 11, 2025
2020 – 2024
United States locations
- U.S. sites
- 51
- U.S. states
- 27
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 629 | Mobile | Alabama | 36693-7003 | — |
| Research Site 614 | Phoenix | Arizona | 85013 | — |
| Research Site 677 | Phoenix | Arizona | 85018 | — |
| Research Site 642 | Long Beach | California | 90806 | — |
| Research Site 644 | Pasadena | California | 91105 | — |
| Research Site 672 | San Diego | California | 92121 | — |
| Research Site 634 | Stamford | Connecticut | 06905 | — |
| Research Site 656 | Washington D.C. | District of Columbia | 20007 | — |
| Research Site 616 | Boca Raton | Florida | 33428 | — |
| Research Site 625 | Maitland | Florida | 32751 | — |
| Research Site 617 | Miami | Florida | 33136 | — |
| Research Site 643 | Ormond Beach | Florida | 32174 | — |
| Research site 645 | St. Petersburg | Florida | 33713 | — |
| Research Site 652 | Tallahassee | Florida | 32308 | — |
| Research Site 621 | Elk Grove Village | Illinois | 60007 | — |
| Research Site 649 | Northbrook | Illinois | 60062 | — |
| Research Site 675 | Peoria | Illinois | 61637 | — |
| Research Site 628 | Rolling Meadows | Illinois | 60008 | — |
| Research Site 624 | Indianapolis | Indiana | 46256 | — |
| Research Site 632 | Kansas City | Kansas | 66160 | — |
| Research Site 653 | New Orleans | Louisiana | 70115 | — |
| Research Site 623 | Baltimore | Maryland | 21201 | — |
| Research Site 633 | Boston | Massachusetts | 02114 | — |
| Research Site 639 | Foxborough | Massachusetts | 02035 | — |
| Research Site 635 | Lawrence | Massachusetts | 01843 | — |
| Research Site 636 | Worcester | Massachusetts | 01655 | — |
| Research Site 613 | Detroit | Michigan | 48201 | — |
| Research Site 612 | Farmington Hills | Michigan | 48334 | — |
| Research Site 638 | St Louis | Missouri | 63110 | — |
| Research Site 664 | St Louis | Missouri | 63131 | — |
| Research Site 668 | Omaha | Nebraska | 68130 | — |
| Research Site 626 | Las Vegas | Nevada | 89106 | — |
| Research Site 667 | Audubon | New Jersey | 08106 | — |
| Research Site 620 | Patchogue | New York | 11772 | — |
| Research Site 663 | Akron | Ohio | 44320 | — |
| Research Site 630 | Toledo | Ohio | 43614-2598 | — |
| Research Site 611 | Oklahoma City | Oklahoma | 73104 | — |
| Research Site 641 | Oklahoma City | Oklahoma | 73104 | — |
| Research Site 615 | Springfield | Oregon | 97477 | — |
| Research Site 647 | Willow Grove | Pennsylvania | 19090 | — |
| Research Site 648 | Knoxville | Tennessee | 37922 | — |
| Research Site 627 | Nashville | Tennessee | 37205 | — |
| Research Site 637 | Nashville | Tennessee | 37215 | — |
| Research Site 662 | Dallas | Texas | 75214 | — |
| Research Site 631 | Houston | Texas | 77030 | — |
| Research Site 650 | Lubbock | Texas | 79410 | — |
| Research Site 619 | Round Rock | Texas | 78681 | — |
| Research Site 676 | Layton | Utah | 84041 | — |
| Research Site 673 | Alexandria | Virginia | 22310 | — |
| Research Site 654 | Virginia Beach | Virginia | 23456 | — |
| Research Site 651 | Milwaukee | Wisconsin | 53226-3596 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 228 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04338022, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04338022 live on ClinicalTrials.gov.